{"id":2771594,"date":"2020-11-18T00:00:00","date_gmt":"2020-11-18T00:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/"},"modified":"2021-03-17T20:32:52","modified_gmt":"2021-03-17T20:32:52","slug":"merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/","title":{"rendered":"Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART)"},"content":{"rendered":"<p>KENILWORTH, N.J., November 18, 2020 \u2013 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of a new website for the global Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART, which was initiated in 2002, is one of the world\u2019s largest and longest-running antimicrobial resistance (AMR) surveillance studies including more than 200 sites across more than 60 countries. <\/p>\n<p>The expanded functionality of the global SMART surveillance website includes heat maps of non-susceptible\/resistance patterns based on the generally accepted standards of professional epidemiology organizations. It also features additional functionality for SMART investigators (depending on location).<\/p>\n<p>\u201cTo sufficiently address the threat of antimicrobial resistance, first we need to understand it. That\u2019s why, alongside antimicrobial innovation, building surveillance capabilities is a core part of our efforts to address AMR,\u201d said Dr. Amanda Paschke, executive director, infectious diseases, Merck Research Laboratories. \u201cAt Merck, we are working to make SMART data more accessible. We\u2019re proud to take this next important step in time with World Antimicrobial Awareness Week.\u201d <\/p>\n<p>&nbsp;<\/p>\n<p><strong>Merck\u2019s Commitment to Infectious Diseases<\/strong><\/p>\n<p>For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases. In addition to a combined portfolio of vaccines and antibacterial, antiviral and antifungal medicines, Merck has multiple programs that span discovery through late-stage development. To learn more about Merck\u2019s infectious diseases pipeline, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated.\">vip2-msd.com\/merckcom-migrated.<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>About Merck<\/strong><\/p>\n<p>For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals \u2013 including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases \u2013 as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect with us on <a href=\"https:\/\/twitter.com\/Merck\">Twitter<\/a>, <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\">Facebook<\/a>, <a href=\"https:\/\/www.instagram.com\/merck\/\">Instagram<\/a>, <a href=\"https:\/\/www.youtube.com\/user\/Merck\">YouTube<\/a> and <a href=\"https:\/\/www.linkedin.com\/company\/merck\">LinkedIn<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/strong><\/p>\n<p>This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<\/p>\n<p>Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.<\/p>\n<p>The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s 2019 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\">www.sec.gov<\/a>).<\/p>\n<p>&nbsp;<\/p>\n<p>Media: <br \/>Pamela Eisele <br \/>(267) 305-3558<br \/>Sarra S. Herzog  <br \/>(201) 669-6570<\/p>\n<p>Investor Contacts: <br \/>Peter Dannenbaum <br \/>(908) 740-1037<br \/>Michael DeCarbo  <br \/>(908) 740-1807<\/p>\n","protected":false},"excerpt":{"rendered":"<p>KENILWORTH, N.J., November 18, 2020 \u2013 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of a new website for the global Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART, which was initiated in 2002, is one of the world\u2019s largest and longest-running antimicrobial resistance (AMR) surveillance studies including more than 200 sites across more than 60 countries. The expanded functionality of the global SMART surveillance website includes heat maps of non-susceptible\/resistance patterns based on the generally accepted standards of professional epidemiology organizations. It also features additional functionality for SMART investigators (depending on location). \u201cTo sufficiently address the threat of antimicrobial resistance, first we need to understand it. That\u2019s why, alongside antimicrobial innovation, building surveillance capabilities is a core part of our efforts to address AMR,\u201d said Dr. Amanda Paschke, executive<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[290,53],"class_list":["post-2771594","news_item","type-news_item","status-publish","hentry","tag-company-statement","tag-corporate-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"KENILWORTH, N.J., November 18, 2020 \u2013 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of a new website for the global Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART, which was initiated in 2002, is one of the world\u2019s largest and longest-running antimicrobial resistance (AMR) surveillance studies including more than 200 sites across more than 60 countries. The expanded functionality of the global SMART surveillance website includes heat maps of non-susceptible\/resistance patterns based on the generally accepted standards of professional epidemiology organizations. It also features additional functionality for SMART investigators (depending on location). \u201cTo sufficiently address the threat of antimicrobial resistance, first we need to understand it. That\u2019s why, alongside antimicrobial innovation, building surveillance capabilities is a core part of our efforts to address AMR,\u201d said Dr. Amanda Paschke, executive\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-17T20:32:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\\\/\",\"name\":\"Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2020-11-18T00:00:00+00:00\",\"dateModified\":\"2021-03-17T20:32:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/","og_locale":"en_US","og_type":"article","og_title":"Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART) - Merck.com","og_description":"KENILWORTH, N.J., November 18, 2020 \u2013 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of a new website for the global Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART, which was initiated in 2002, is one of the world\u2019s largest and longest-running antimicrobial resistance (AMR) surveillance studies including more than 200 sites across more than 60 countries. The expanded functionality of the global SMART surveillance website includes heat maps of non-susceptible\/resistance patterns based on the generally accepted standards of professional epidemiology organizations. It also features additional functionality for SMART investigators (depending on location). \u201cTo sufficiently address the threat of antimicrobial resistance, first we need to understand it. That\u2019s why, alongside antimicrobial innovation, building surveillance capabilities is a core part of our efforts to address AMR,\u201d said Dr. Amanda Paschke, executive","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/","og_site_name":"Merck.com","article_modified_time":"2021-03-17T20:32:52+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/","name":"Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2020-11-18T00:00:00+00:00","dateModified":"2021-03-17T20:32:52+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-unveils-new-website-for-global-study-for-monitoring-antimicrobial-resistance-trends-smart\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Unveils New Website for Global Study for Monitoring Antimicrobial Resistance Trends (SMART)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f1cd92cb-f5f0-40f5-985e-339f20e310f8","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/2020\/11\/SMART-Launch-COMPANY-STATEMENT-11.12.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/2771594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/2771594\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=2771594"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=2771594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}